Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07566208 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Using Mirabegron to Control Arrhythmia-1

Study acronym: MACH-1
StatusNot Yet Recruiting
PhasePhase 2
Started2026-05
View on ClinicalTrials.gov ↗

Amendment history

2026-05-04
Study Status, Study Description, Arms and Interventions, Outcome Measures v1
Study description+45 characters
[...] 2. Description of Sites/Facilities Enrolling Participants: WeThe investigators will enroll patients in the cardiac device clinic at the Sm [...] p on patients with ICDs. Description of Study Intervention: WeThe investigators will give the patients 50 mg/day of mirabegron orally for t [...] ee months. The primary endpoint takes 2 months to complete. WeThe investigators will call the patient at 3 months to determine if there are any complications. The patient will then exit the study.
2026-04-29
Original filing
To evaluate mirabegron's effect on ventricular arrhythmia control. The study will be conducted in ambulatory patients with ventricular tachycardia (VT), organic heart diseases, and an implantable cardioverter-defibrillator (ICD). The investigators will perform a pilot study involving 20 patients. Each will receive 50 mg of mirabegron. All will have neuECG recordings made before and 2 months after mirabegron. The data will be analyzed to test the proposed hypothesis.
Trial Details
NCT Number NCT07566208
Lead Sponsor Cedars-Sinai Medical Center
Conditions Ventricular Arrhythmias and Cardiac Arrest
Enrollment 20 participants
Start Date 2026-05
Primary Completion 2028-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-06